Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 November 2023 | Story Ouma Ngoepe | Photo SUPPLIED
Liezl Geldenhuys (ZZ2), Mellisa Pringle (Lasec), Ouma Ngoepe (CMBG), Prof Maryna de Wit (SFSD), Dr Mariana Erasmus (CMBG), Bernadine Taljaard (ZZ2), Khezwo Nematshema (SFSD), Shahiëda Cloete (SFSD), Jan Andries Viktor (SFSD), Vuyelwa Nkoi (SFSD).
Liezl Geldenhuys (ZZ2), Mellisa Pringle (Lasec), Ouma Ngoepe (CMBG), Prof Maryna de Wit (SFSD), Dr Mariana Erasmus (CMBG), Bernadine Taljaard (ZZ2), Khezwo Nematshema (SFSD), Shahiëda Cloete (SFSD), Jan Andries Viktor (SFSD), Vuyelwa Nkoi (SFSD).

The Centre for Mineral Biogeochemistry (CMBG) at the University of the Free State (UFS) was part of another successful Tritech National Science and Technology Fair 2023 – an exciting STEM (Science, Technology, Engineering, and Mathematics) research competition.

The UFS has partnered with Tritech and other sponsors since 2021 to bridge the gap between high school and tertiary education. Tritech, which started in 2008 and is open to all Grade 7-12 learners, aims to equip them for tertiary education by introducing them to scientific research and incorporating modern technology in research. This is an annual competition that starts at the regional level and goes all the way to the national level, with the national competition held at the Merensky High School, in Tzaneen, Limpopo from 20-21 October 2023.

Schools from across the country take part in the fair, but learners compete in groups rather than schools. 

Every year the Tritech Nationals are divided into four main activities over the weekend: 
  1. On the Friday afternoon the learners present their STEM projects in which they have identified a problem in a community, do research to find a solution, do experiments to test if the solution will solve the problem, then test the solution in the community, and lastly, present their findings to a group of judges and learners in similar fields. Fields include Life Sciences, Engineering and Design, Maths, Science and Technology, Environmental and Social Sciences, Health Sciences and Agricultural Sciences.
  2. Friday evening is usually a fun activity for the learners.
  3. On Saturday morning the learners are exposed to work-related activities that give them insight into professions they could pursue in the science field. This activity is sponsored and presented by the UFS. 
  4. The last activity of the weekend is the prize-giving on Saturday afternoon where the learners get rewarded for the quality of their projects and honour, celebrate, and encourage excellence. 

“Every year the CMBG includes different departments from the UFS in alignment with the theme for the event, to ignite a lasting passion for innovation toward promising careers in the STEM fields. In 2022 the theme for Tritech was “Crime Scene Investigators” and the CMBG team created a very realistic crime scene and laboratory setup to teach the learners about Forensic Science. The learners scored our CSI activity as the best for the weekend and we knew that for the 2023 Nationals, we had our work cut out to do even better,” says Dr Erasmus. 

Learning about food health and safety

This year, Prof Maryna de Wit and her students from the Department of Sustainable Food Systems and Development (SFSD) joined the CMBG team, to introduce learners to food health and safety, food preservation, food systems and development, as well as sensory analyses. 

Island, shipwrecks, and wilderness survival

Dr Mariana Erasmus, Deputy Director of the Centre for Mineral Biogeochemistry (CMBG), spearheads the Tritech team from the UFS. CMBG, as part of its community outreach programme, is not only a sponsor of the event but is also the organiser of the main activity together with another UFS department. 

Dr Erasmus says the theme for Tritech 2023 was “Survival MasterChef”, where for the two activity events, the Tritech learners were “stranded” on an island. This exercise was a great way to promote leadership qualities, encourage creativity and confidence, promote teamwork and active communication, and increase critical thinking in learners, while they got to know more about food health and safety practices.

“It was all island, shipwrecks, and wilderness survival at this year’s event where learners had to survive after being ‘stranded’ on an island. To escape, the learners had to build a boat and while they waited to be rescued, they needed to adapt to island life to survive by preparing healthy meals, as well as preparing meals and drinks to treat dehydration and scurvy,” says Dr Erasmus. 

“During the prize-giving, some of the learners received shadowing opportunities at the UFS and other sponsors to advance their education. Bronze, silver, and gold medals, together with participation certificates, were awarded to other deserving learners.” 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept